350 related articles for article (PubMed ID: 15947793)
1. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
2. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
4. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
[TBL] [Abstract][Full Text] [Related]
6. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
7. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
8. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
[TBL] [Abstract][Full Text] [Related]
10. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
11. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
12. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
[TBL] [Abstract][Full Text] [Related]
13. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
14. Deficient deletion of apoptotic cells by macrophage migration inhibitory factor (MIF) overexpression accelerates photocarcinogenesis.
Honda A; Abe R; Yoshihisa Y; Makino T; Matsunaga K; Nishihira J; Shimizu H; Shimizu T
Carcinogenesis; 2009 Sep; 30(9):1597-605. PubMed ID: 19584138
[TBL] [Abstract][Full Text] [Related]
15. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
16. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
17. Myc lacks E2F1's ability to suppress skin carcinogenesis.
Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
[TBL] [Abstract][Full Text] [Related]
18. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
20. Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts.
Lindström MS; Wiman KG
Oncogene; 2003 Aug; 22(32):4993-5005. PubMed ID: 12902982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]